The ED Telehealth Market
Hims, Ro/Roman, BlueChew, Rugiet, direct-to-consumer ED prescribing
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Underlying drugs FDA-approved; compounded formulations are not
Reference only. Not medical advice.
What can go wrong
Asynchronous prescribing can under-emphasize the cardiovascular significance of ED and the nitrate contraindication. Compounded chewables and combination products are not FDA-approved and carry the dosing-consistency uncertainties of compounding. Subscription auto-refill models have drawn consumer complaints about cancellation friction.
This is something to take to a clinician. The Atlas can tell you what is known about the ed telehealth market in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Since roughly 2017-2019, online men's-health platforms have reshaped how ED drugs are sold in the US. Hims, Ro (Roman), BlueChew, and Rugiet pair an asynchronous telehealth visit with mail-order generic sildenafil/tadalafil. The active ingredients are FDA-approved generics; many platforms upsell compounded chewables, troches, and combination products that are NOT individually FDA-approved. Convenience and discretion are real; the markups over wholesale generic cost are large.
A multibillion-dollar industry built on $0.30 generic pills and slick branding.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
These platforms do not change the pharmacology of ED drugs, they change distribution. A patient completes an online intake; a licensed clinician (often via store-and-forward review rather than live video) issues a prescription; a partnered or affiliated pharmacy ships generic PDE5 inhibitor or a compounded formulation on a recurring subscription.
What the marketing skips
The drug in most of these subscriptions is generic sildenafil, which can cost a cash-pay patient well under a dollar per pill at a discount pharmacy. The platform's value is brand, convenience, and packaging, not a superior molecule. 'Personalized' or 'clinically dosed' compounded chewables are not FDA-approved products; the marketing language often implies a clinical advantage that controlled evidence does not establish.
What people get wrong
Often saidOnline ED brands sell a special, better version of Viagra
ActuallyThe active ingredient is almost always generic sildenafil or tadalafil. The premium pays for convenience and branding, not a superior drug.
Who profits, and who pushes back
US Food and Drug Administration
Compounded ED products are not FDA-approved; marketing that implies a compounded chewable is the same as an approved drug, or that promotes untested sildenafil-tadalafil combinations, is misleading and has drawn warning letters.
Telehealth-safety researchers
Store-and-forward asynchronous prescribing can shortcut blood-pressure checks, nitrate-interaction screening, and the cardiovascular workup that an ED presentation warrants, trading clinical thoroughness for speed and convenience.
Consumer-pricing and pharmacy critics
The active ingredients are cheap generics, so recurring subscription pricing for compounded or branded-feeling formulations often represents a large markup over what the same molecule costs at a retail pharmacy with a discount card.
How we got here
The category emerged after generic sildenafil arrived in December 2017 (Teva first), collapsing the per-pill cost and making a direct-to-consumer subscription economically attractive. Roman/Ro and Hims launched men's-health telehealth around 2017-2018; BlueChew popularized the chewable angle; Hims & Hers went public via SPAC in 2021.
- 2017Generic sildenafil launches; DTC men's-health startups form
- 2018Hims and Roman scale ED telehealth
- 2021Hims & Hers goes public (NYSE: HIMS)
- 2024Hims & Hers reports ~$1.5B total revenue per SEC filings
Set against the alternatives
Compared with the traditional path of an in-person physician visit and a retail-pharmacy fill, these platforms trade clinical depth for discretion, speed, and home delivery; the trade-off is reduced face-to-face screening and frequent upselling of compounded products. Among the platforms themselves, Hims and Ro are the broad, well-capitalized generalists (Hims & Hers is publicly traded), while BlueChew and Rugiet differentiate on novel delivery formats such as chewables and sublingual multi-ingredient troches. Versus simply buying generic sildenafil or tadalafil with a pharmacy discount program, the platforms usually cost more per dose, with the premium reflecting convenience and brand experience rather than a superior molecule.
| Platform | Visit model | Signature offering | Note |
|---|---|---|---|
| Hims & Hers | Async intake | Generic plus compounded combos | Largest, publicly traded |
| Ro (Roman) | Async / hybrid | Generic sildenafil, tadalafil | Broad men's-health menu |
| BlueChew | Async intake | Compounded chewables | Received FDA warning letter (2025) |
| Rugiet | Async intake | Compounded sublingual combo | Multi-ingredient troche focus |
What we do not know
- Do asynchronous telehealth ED visits achieve cardiovascular and drug-interaction screening comparable to in-person care?
- What are the real-world safety outcomes of widely sold compounded sildenafil-tadalafil combination products?
- How will tightening FDA enforcement on compounding and combination claims reshape these business models?
- Does subscription-based dispensing improve adherence and outcomes, or mainly maximize recurring revenue?
- How many telehealth ED users have undiagnosed cardiovascular disease that an in-person visit would have caught?
What could change
Regulatory tighteningIncreasing FDA scrutiny of compounded ED combinations and same-as-approved marketing claims (warning letters in 2025)Platform diversificationExpansion from ED into broader men's and women's health, weight management, and mental health categoriesFormat innovationContinued push into chewables, sublingual troches, and combination formats as marketing differentiatorsInsurance and pricing pressurePossible shift as generic transparency tools and price competition challenge subscription markups
At a glance
- Model
- Async telehealth + mail pharmacy
- Hims & Hers 2024 revenue
- ~$1.5B (all categories), per company SEC filings
- Core drugs
- Generic sildenafil, tadalafil
- Common upsell
- Compounded chewables / sublingual combos
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about The ED Telehealth Market. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- Children and teenagers. We have not checked what is known about younger people.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.